Hey There : )
Unlisted Shares
Price Chart
1W
1M
1Y
MAX
High
-
Low
-
Return
-
Anglo French Drugs & Industries Essentials
As of September 08, 2024, Anglo French Drug & Industries, Unlisted share price is ₹1320.00 per share and the face value is ₹10.00/share. The lot size of Anglo French Drug & Industries is 120 shares. The 52-week high for Anglo French Drug & Industries stock price is ₹1828, while the 52-week low is ₹1320
An International Securities Identification Number (ISIN) is a code that uniquely identifies a specific securities issue. The numbers are allocated by a country's respective national numbering agency (NNA).
Value of a security, as stated by its issuer. It has no relation with market price of the stock.
Total shares or total number of shares outstanding represents the amount of stock on the open market, including shares held by institutional investors and restricted shares held by insiders and company officers.
Gross income refers to the total income earned by an individual on a pay check before taxes and other deductions. It comprises all incomes received by an individual from all sources – including wages, rental income, interest income, and dividends.
It is the final profit left over after subtracting all operating and non operating items from net revenue.
It is the profit allocated to each outstanding share of common stock.
It is a valuation parameter that measures the company's current share price relative to its per-share earnings. Generally, high P/E is Overvalued & low P/E is Undervalued.
It shows the relationship between the current price and the book value of each share. A lower P/B ratio can mean that the stock is undervalued.
Market capitalization is the aggregate valuation of the company based on its current share price and the total number of outstanding shares.
It measures companys total value, which includes market capitalization, debt and excludes cash.
It calculates the per share value of a company based on its equity available to common shareholders
Intrinsic value is the anticipated value of a company or stock determined through fundamental analysis. It is also referred to as the price a rational investor is willing to pay for an investment, given its level of risk.
A sector is an area in which businesses share the same or a related product or service. It can also be known as an industry or market that shares common operating characteristics
Subsectors are the divisions of a sector. They are areas that vary from the rest of the sector substantially enough to justify creating a plan just for the subsector.
Category is defined as a class or division of things regarded as having particular shared characteristics.
It indicates the amount of money a company brings in from its ongoing and regular operations over a fixed period of time.
It shows the net flows of cash that are used to fund the company, which include transactions involving debt, equity, and dividends.
Anglo French Drugs & Industries Growth
Compounded Sales Growth
Compounded Profit Growth
Return On Equity
Highlights
- About the Company: Anglo French Drugs & Industries Ltd. ("AFDIL"), is primarily involved in the manufacturing of pharmaceutical formulation, which primarily involves mixing various chemical compounds into active drugs/ingredients. The company is the formulator, supplier, and distributor of drugs and medicines across nutraceuticals, CNS, skin, and respiratory segments. From being an importer of medicines in 1923, the company has emerged as the manufacturer, marketer, and distributor of over 350 products across the world; over 100 years
- Revenue Growth: The company's revenue has experienced a substantial decrease, reducing from ₹165 crore in FY22 to ₹102 crore in FY23, indicating a negative growth rate of -38%. Over the past years, the company's revenue has consistently increased, unlike FY23, which has represented a decrease. The company has achieved a compound annual growth rate (CAGR) of -2% from FY18 to FY23.
- Notable Investors: The company has some prominent names on the captable such as Life Insurance Corporation of India holds a 7% and Ninaad Finance & Properties holds a 10% stake in the company.
- Investment Thesis: Despite being in operation for six decades, the company's annual revenue remains below ₹170 Crores, indicating a potential efficiency concern. While the company recorded a profit (PAT) of ₹190 Crores in FY23, it's crucial to note that this figure includes a one-time gain of ₹299.68 Crores from the sale of brands. Excluding this exceptional item, the company incurred an operational loss of ₹40 Crores, highlighting underlying financial challenges. This raises inquiries about the company's overall financial performance and its capacity to effectively overcome current obstacles.
Business Rating
Our Team
